BioSpace News Archive

According to Nova one advisor, the global Non-opioid Pain Treatment market size is expected to hit around USD 78.01 billion by 2030 from valued at USD 38.94 billion in 2021 and growing at a CAGR of 8.60% from 2022 to 2030.

Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, announced the appointment of Michael L. Meyers, M.D., Ph.D., to its Board of Directors.

Plandai Biotechnology, Inc. announces its entry into a non-binding letter of intent with EV Hotel Corp., a Georgia corporation.

Mallinckrodt plc, a global specialty pharmaceutical company, announced that it has appointed Susan Silbermann to its Board of Directors, effective October 5, 2022.

Taysha Gene Therapies, Inc. today announced two poster presentations at the upcoming 29th Annual Meeting of the European Society of Gene & Cell Therapy (ESGCT) in cooperation with the British Society of Gene & Cell Therapy (BSGCT) taking place in Edinburgh, Scotland from October 11-14, 2022.

Plus Therapeutics, Inc. announced that the Company will report third quarter 2022 financial results on Thursday, October 20, 2022, after market close.

Bio-Techne Corporation (NASDAQ: TECH) today announced the expansion of the Advanced Cell Diagnostics (ACD)-branded RNAscope™ in situ hybridization (ISH) portfolio with the release of new automated co-detection assays specifically designed for the Roche DISCOVERY ULTRA Platform, enabling simultaneous detection of RNA and protein on the same tissue section.

CytoSorbents Corporation announced today that the U.S. Army Medical Research Acquisition Activity (USAMRAA) has awarded the Company a three-year Phase III contract valued at $4,292,641 to customize the design of the HemoDefend-BGA™ filter for sterile integration into collections systems for freeze-dried plasma processing to generate freeze-dried universal plasma.

FDA clearance introduces first immunohistochemistry IHControls panel for evaluating breast cancers.

Revelation Biosciences Inc. today announced an exclusive worldwide license agreement with Vanderbilt University, Nashville TN, USA (Vanderbilt) to develop and commercialize phosphorylated hexaacyl disaccharide (PHAD), for treating or preventing infections.